SOLARA ACTIVE PHARMA SCIENCES LIMITED |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 492.4 INR | -0.63% |
|
-11.06% | +36.33% |
| 05-10 | Solara Active Pharma to Raise 4.50 Billion Via Rights Issue | MT |
| 04-08 | Solara Active Pharma Sciences Limited Approves Appointment of Mohan Muthunarayanan as an Executive Director | CI |
Presenter SpeechAbhishek Singhal (Executives)A very good afternoon to all of you, and thank yo...
This article is reserved for subscribers
Signed up already?
Log InNot subscribed yet?
Subscribe
Solara Active Pharma Sciences Limited is an India-based company offering diversified, commercial active pharmaceutical ingredients (APIs) and contract manufacturing services in over 70 countries. The Company operates through the API segment. Its commercial and research and development products include Albendazole, Aprepitant (Antiemetic), Artesunate, Brivaracetam (Antiepileptic), Bumetanide (Inj) (Loop Diuretic), Buspirone HCL (Anxiolytic), Cetirizine Dihydrochloride, Chlorpromazine Hydrochloride, Cinacalcet Hydrochloride (Calcimimetic Agent), Citicoline Sodium (Anticonvulsant), Colchicine (Antigout Agent), Colesevelam Hydrochloride, Cycloserine (Antitubercular), Ethacrynic Acid (Cardiovascular Agent), Hydralazine Hydrochloride (Anti-Hypertensive), Ibuprofen Sodium Dihydrate (Anti-inflammatory), Mesna (Antineoplastic Detoxifying Agent), Mirabegron (OAB Treatment), Pentoxifylline, and others. The Company works with pharmaceutical companies from North America, Europe, and Japan.
Sector
Pharmaceuticals
Calendar
2024-08-12
- Q1 2025 Earnings Release (Projected)
Trading Rating
Investor Rating
ESG Refinitiv
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
3
Last Close Price
492.4
INR
Average target price
350
INR
Spread / Average Target
-28.91%
EPS Revisions
Quarterly revenue - Rate of surprise
| 1st Jan change | Capi. | |
|---|---|---|
| +36.33% | 212M | |
| +30.38% | 684B | |
| +26.51% | 568B | |
| -4.36% | 361B | |
| +19.30% | 329B | |
| +3.73% | 284B | |
| +16.70% | 240B | |
| +8.78% | 208B | |
| -7.93% | 200B | |
| +7.68% | 166B |
- Stock Market
- Equities
- SOLARA Stock
- News Solara Active Pharma Sciences Limited
- Transcript : Solara Active Pharma Sciences Limited, Q3 2021 Earnings Call, Feb 03, 2021